Ardeshir Talieh
Internal Medicine · San Luis Obispo, CANPI 1467454819
Payments from drug & device makers
Across 613 payments — averaging $18.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Amgen$1K
- AbbVie$1K
- AstraZeneca$1K
- Pfizer$842
- Novo Nordisk$730
- plus $5K from 37 others
What the payments were for
- Food & beverage$11,10499%
- Education$871%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$11,191 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 118 | $156,788 |
| EliquisApixaban | 151 | $154,305 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 126 | $103,195 |
| ProliaDenosumab | 44 | $74,244 |
| TrulicityDulaglutide | 41 | $62,924 |
| MounjaroTirzepatide | 32 | $50,630 |
| XareltoRivaroxaban | 42 | $48,448 |
| MyrbetriqMirabegron | 44 | $38,150 |
| JanuviaSitagliptin Phosphate | 17 | $26,896 |
| JardianceEmpagliflozin | 15 | $23,359 |
| Repatha SureclickEvolocumab | 37 | $22,716 |
| Spiriva RespimatTiotropium Bromide | 34 | $18,046 |
| CreonLipase/Protease/Amylase | 15 | $17,235 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $9,150 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $9,137 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $730 | $156,788118 claims |
| PfizerEliquis | $842 | $154,305151 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $1,421 | $119,692156 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $498 | $113,55473 claims |
| AmgenProlia | $1,363 | $74,24444 claims |
| Johnson & JohnsonXarelto | $484 | $48,44842 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $467 | $41,40549 claims |
| Astellas Pharma US IncMyrbetriq | $172 | $38,15044 claims |
| MerckJanuvia | $152 | $26,89617 claims |
| AbbVieCreon, Synthroid | $1,230 | $19,90337 claims |
| Sanofi-aventis U.S. LLCLantus | $165 | $2,32119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in San Luis Obispo
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.